Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | MST1R | Q04912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480129 | 0.75 | MAPT (0.48) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL12480398 | 0.75 | NOS1 (0.52) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL402053 | 0.75 | MAPT (0.48) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL2366705 | 0.75 | NOS1 (0.52) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL30911413 | 0.75 | NOS1 (0.39) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL3272822 | 0.73 | PLK4 (0.44) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL29696517 | 0.73 | PLK4 (0.44) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL18237595 | 0.72 | MAPT (0.42) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL35211261 | 0.72 | DYRK1A (0.40) | NOS1FGFR1MAPTPLK4CHEK1 | |
| SCHEMBL35211342 | 0.72 | ROCK1 (0.42) | NOS1FGFR1MAPTPLK4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | IGF1R, IGFBP3, INSR | NOS1 2230/4885FGFR1 47/4885MAPT 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.